

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-HA [C179] Standard Size Ab03384-2.0

Isotype and Format: Mouse IgG2a, Kappa

Clone Number: C179

Alternative Name(s) of Target: Hemagglutinin HA1; Hemagglutinin; Hemagglutinin HA2

UniProt Accession Number of Target Protein: C7S226

Published Application(s): crystallization, in vitro, in vivo, IP, neutralizing, ELISA

Published Species Reactivity: H1N1, H2N2

Immunogen: The original antibody was generated by immunizing BALB/c mice with A/Okuda/57 (H2N2) strain of influenza virus.

Specificity: The antibody binds an epitope in the HA stem. The epitope consists of residues from the N-and C-terminal regions of HA1 (residues 38, 40, 42, 291 to 293, and 318) and the N-terminal portion of HA2 (residues 18 to 21, 38, 41 to 43, 45, 46, 52, and 56), including helix A. The antibody cross-neutralizes multiple influenza virus subtypes, including H1, H2, H5, H6, and H9 viruses but does not recognize the H3N2 subtype strains and the influenza B type virus strain.

Application Notes: The antibody recognized the hemagglutinin (HA) glycoprotein by immunoprecipitation assays. Cell-cell fusion assay was performed on CV-1 cells infected with the influenzavirus H1 and H2 strains. The antibody inhibited the fusion activity of HA and thus results in virus neutralization and inhibition of cell-cell fusion (Okuno et al., 1993; PMID: 7682624). The antibody binding to HA on CV-1 cells was confirmed by immunostaining (Sagawa et al., 1996; PMID: 8757990). The antibody exhibited potent in vitro neutralizing activity against H1N1 and H2N2, followed by H1N1pdm09, and to a much lesser extent, H5N1 viruses. In vivo studies showed that the preventive administration of the antibody via the intranasal (Sakabe et al., 2010; PMID: 20849879) or intraperitoneal route led to the complete protection against H1N1, H1N1pdm09, and some H5N1 virus infection in mice (US5684146A, Sakabe et al., 2010; PMID: 20849879). The therapeutic administration of the antibody was less effective against H1N1pdm09 and H5N1 viruses compared to the seasonal H1N1 viruses, although the antibody was able to extend the survival period of H1N1pdm09-infected mice (Sakabe et al., 2010; PMID: 20849879). The scFv fragment on the antibody was employed to detect human influenza A type virus by the ELISA analysis (US5684146A). The Fab fragment bound to several influenza A virus group 1 subtypes, including H1, H2, H5, H6, and H9, with high to intermediate affinity (Kd \approx 2 to 200 nM), as determined by biolayer interferometry (BLI). Crystal structure of the Fab fragment in complex with an H2N2 influenza virus hemagglutinin was determined (Dreyfus et al., 2013; PMID: 23552413).

Antibody First Published in: Okuno et al. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol. 1993 May;67(5):2552-8.

PMID:7682624

Note on publication: The original paper describes the generation and characterization of the antibody.

Product Form

Size: 200 μg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.